P. Adamson, F. Bray, A. S. Costantini, M. Tao, E. Weiderpass et al., Time trends in the registration of Hodgkin and non-Hodgkin lymphomas in Europe, Eur J Cancer Oxf Engl, vol.43, issue.2, pp.391-401, 1990.

M. Sant, C. Allemani, C. Tereanu, D. Angelis, R. Capocaccia et al., Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project, Blood, vol.116, pp.3724-3758, 2010.

D. D. Alexander, P. J. Mink, H. Adami, E. T. Chang, P. Cole et al., The non-Hodgkin lymphomas: A review of the epidemiologic literature, Int J Cancer, vol.120, issue.S12, pp.1-39, 2007.

L. M. Morton, J. N. Sampson, J. R. Cerhan, J. J. Turner, C. M. Vajdic et al., Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project, J Natl Cancer Inst Monogr, issue.48, pp.1-14, 2014.

N. Becker, S. De-sanjose, A. Nieters, M. Maynadié, L. Foretova et al., Birth order, allergies and lymphoma risk: results of the European collaborative research project Epilymph, Leuk Res, vol.31, issue.10, pp.1365-72, 2007.

N. Becker, J. Fortuny, T. Alvaro, A. Nieters, M. Maynadié et al., Medical history and risk of lymphoma: results of a European case-control study (EPILYMPH), J Cancer Res Clin Oncol, vol.135, issue.8, pp.1099-107, 2009.

M. S. Linet, C. M. Vajdic, L. M. Morton, A. J. Roos, . De et al., Medical History, Lifestyle, Family History, and Occupational Risk Factors for Follicular Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project, JNCI Monogr, issue.48, pp.26-40, 2014.

J. R. Cerhan, R. B. Wallace, A. R. Folsom, J. D. Potter, T. A. Sellers et al., Medical history risk factors for non-Hodgkin's lymphoma in older women, J Natl Cancer Inst, vol.89, issue.4, pp.314-322, 1997.

P. M. Bracci, Y. Benavente, J. J. Turner, O. Paltiel, S. L. Slager et al., Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project, J Natl Cancer Inst Monogr, issue.48, pp.52-65, 2014.

A. 't-mannetje, D. Roos, A. J. Boffetta, P. Vermeulen, R. Benke et al., Occupation and Risk of Non-Hodgkin Lymphoma and Its Subtypes: A Pooled Analysis from the InterLymph Consortium. Environ Health Perspect, 2015.

P. Cocco, A. Mannetje, D. Fadda, M. Melis, N. Becker et al., Occupational exposure to solvents and risk of lymphoma subtypes: results from the Epilymph case-control study, Occup Environ Med, vol.67, issue.5, pp.341-348, 2010.
URL : https://hal.archives-ouvertes.fr/hal-01260431

P. Cocco, G. Satta, S. Dubois, C. Pili, M. Pilleri et al., Lymphoma risk and occupational exposure to pesticides: results of the Epilymph study, Occup Environ Med, vol.70, issue.2, pp.91-99, 2013.

L. Costas, C. Infante-rivard, J. Zock, M. Van-tongeren, P. Boffetta et al., Occupational exposure to endocrine disruptors and lymphoma risk in a multi-centric European study, Br J Cancer, vol.112, issue.7, pp.1251-1257, 2015.

A. Espinosa, J. Zock, Y. Benavente, P. Boffetta, N. Becker et al., Occupational exposure to immunologically active agents and risk for lymphoma: the European Epilymph case-control study, Cancer Epidemiol, vol.37, issue.4, pp.378-84, 2013.

R. Casey, P. Brennan, N. Becker, P. Boffetta, P. Cocco et al., Influence of familial cancer history on lymphoid neoplasms risk validated in the large European case-control study epilymph, Eur J Cancer Oxf Engl, vol.42, issue.15, pp.2570-2576, 1990.

M. Melbye, H. O. Adami, H. Hjalgrim, and B. Glimelius, Ultraviolet light and non-Hodgkin's lymphoma, Acta Oncol Stockh Swed, vol.35, issue.6, pp.655-662, 1996.

A. M. Hughes, B. K. Armstrong, C. M. Vajdic, J. Turner, A. E. Grulich et al., Sun exposure may protect against non-Hodgkin lymphoma: a case-control study, Int J Cancer J Int Cancer, vol.112, issue.5, pp.865-71, 2004.

R. Casey, K. Piazzon-fevre, N. Raverdy, M. Forzy, B. Tretare et al., Case-control study of lymphoid neoplasm in three French areas: description, alcohol and tobacco consumption, Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP, vol.16, issue.2, pp.142-50, 2007.

P. M. Bracci and E. A. Holly, Tobacco use and non-Hodgkin lymphoma: results from a population-based casecontrol study in the San Francisco Bay Area, California. Cancer Causes Control CCC, vol.16, pp.333-379, 2005.

K. E. Smedby, J. N. Sampson, J. J. Turner, S. L. Slager, M. Maynadié et al., Medical history, lifestyle, family history, and occupational risk factors for mantle cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project, J Natl Cancer Inst Monogr, issue.48, pp.76-86, 2014.

J. F. Simard, F. Baecklund, E. T. Chang, E. Baecklund, H. Hjalgrim et al., Lifestyle factors, autoimmune disease and family history in prognosis of non-hodgkin lymphoma overall and subtypes, Int J Cancer, vol.132, issue.11, pp.2659-66, 2013.

B. L. Frederiksen, N. Brown-p-de, S. O. Dalton, M. Steding-jessen, and M. Osler, Socioeconomic inequalities in prognostic markers of non-Hodgkin lymphoma: Analysis of a national clinical database, Eur J Cancer, vol.47, issue.6, pp.910-917, 2011.

C. Bray, D. S. Morrison, and P. Mckay, Socio-economic deprivation and survival of non-Hodgkin lymphoma in Scotland. Leuk Lymphoma, vol.49, pp.917-940, 2008.

B. L. Frederiksen, S. O. Dalton, M. Osler, M. Steding-jessen, and N. Brown-p-de, Socioeconomic position, treatment, and survival of non-Hodgkin lymphoma in Denmark -a nationwide study, Br J Cancer, vol.106, issue.5, p.988, 2012.

A. Smith, S. Crouch, D. Howell, C. Burton, R. Patmore et al., Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma, Cancer Epidemiol, vol.39, issue.6, pp.1103-1115, 2015.

D. Koh, T. Kim, Y. Yoon, K. Shin, and S. Yoo, Lymphohematopoietic cancer mortality and morbidity of workers in a refinery/petrochemical complex in Korea. Saf Health Work, vol.2, pp.26-33, 2011.

C. Tseng, Diabetes, insulin use, and non-Hodgkin lymphoma mortality in Taiwan, Metabolism, vol.61, issue.7, pp.1003-1012, 2012.

T. R. Mikuls, J. O. Endo, S. E. Puumala, P. A. Aoun, N. A. Black et al., Prospective study of survival outcomes in Non-Hodgkin's lymphoma patients with rheumatoid arthritis, J Clin Oncol Off J Am Soc Clin Oncol, vol.24, issue.10, pp.1597-602, 2006.

J. Ji, X. Liu, K. Sundquist, and J. Sundquist, Survival of cancer in patients with rheumatoid arthritis: a follow-up study in Sweden of patients hospitalized with rheumatoid arthritis 1 year before diagnosis of cancer, Rheumatology, vol.50, issue.8, pp.1513-1521, 2011.

C. Tarella, D. Caracciolo, P. Gavarotti, C. Argentino, F. Zallio et al., Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograft, Bone Marrow Transplant, vol.26, issue.11, pp.1185-91, 2000.

L. Weiss, T. Melchardt, S. Habringer, A. Boekstegers, C. Hufnagl et al., Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma, Ann Oncol, vol.25, issue.1, pp.171-177, 2014.

F. Hong, T. M. Habermann, L. I. Gordon, H. Hochster, R. D. Gascoyne et al., The role of body mass index in survival outcome for lymphoma patients: US intergroup experience, Ann Oncol, vol.25, issue.3, pp.669-74, 2014.

J. A. Jones, L. E. Fayad, L. S. Elting, and M. A. Rodriguez, Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma, Leuk Lymphoma, vol.51, issue.9, pp.1649-57, 2010.

O. Landgren, H. Andrén, B. Nilsson, A. Ekbom, and M. Björkholm, Risk profile and outcome in Hodgkin's lymphoma: is obesity beneficial? Ann Oncol, vol.16, pp.838-878, 2005.

F. P. Boscoe and M. J. Schymura, Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, BMC Cancer, vol.6, p.264, 1993.

T. E. Robsahm, S. Tretli, A. Dahlback, and J. Moan, Vitamin D3 from sunlight may improve the prognosis of breast-, colon-and prostate cancer (Norway). Cancer Causes Control CCC, vol.15, pp.149-58, 2004.

W. B. Grant and C. F. Garland, The Association of Solar Ultraviolet B (UVB) with Reducing Risk of Cancer: Multifactorial Ecologic Analysis of Geographic Variation in Age-adjusted Cancer Mortality Rates, Anticancer Res, vol.26, issue.4A, pp.2687-99, 2006.

J. Ji, A. Försti, J. Sundquist, P. Lenner, and K. Hemminki, Survival in non-Hodgkin's lymphoma by histology and family history, J Cancer Res Clin Oncol, vol.135, issue.12, pp.1711-1717, 2009.

L. A. Anderson, R. M. Pfeiffer, J. S. Rapkin, G. Gridley, L. Mellemkjaer et al., Survival Patterns Among Lymphoma Patients With a Family History of Lymphoma, J Clin Oncol, vol.26, issue.30, pp.4958-65, 2008.

X. Han, T. Zheng, F. M. Foss, S. Ma, T. R. Holford et al., Alcohol consumption and non-Hodgkin lymphoma survival, J Cancer Surviv Res Pract, vol.4, issue.2, pp.101-110, 2010.
URL : https://hal.archives-ouvertes.fr/hal-01260433

T. Battaglioli, G. Gorini, A. S. Costantini, P. Crosignani, L. Miligi et al., Cigarette smoking and alcohol consumption as determinants of survival in non-Hodgkin's lymphoma: a population-based study, Ann Oncol Off J Eur Soc Med Oncol ESMO, vol.17, issue.8, pp.1283-1292, 2006.

R. Talamini, J. Polesel, M. Spina, E. Chimienti, D. Serraino et al., The impact of tobacco smoking and alcohol drinking on survival of patients with non-Hodgkin lymphoma, Int J Cancer J Int Cancer, vol.122, issue.7, pp.1624-1633, 2008.

S. M. Geyer, L. M. Morton, T. M. Habermann, C. Allmer, S. Davis et al., Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma: a population-based study, Cancer, vol.116, issue.12, pp.2993-3000, 2010.

R. Gressin, N. Daguindau, A. Tempescul, A. Moreau, S. Carras et al., FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIAL, Hematol Oncol, vol.35, pp.141-143, 2017.

L. Gouill, S. Thieblemont, C. Oberic, L. Moreau, A. Bouabdallah et al., Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma, N Engl J Med, vol.377, issue.13, pp.1250-60, 201728.
URL : https://hal.archives-ouvertes.fr/hal-01610976

A. Keys, F. Fidanza, M. J. Karvonen, N. Kimura, and H. L. Taylor, Indices of relative weight and obesity, J Chronic Dis, vol.25, issue.6, pp.329-372, 1972.

M. Schemper and T. L. Smith, A note on quantifying follow-up in studies of failure time, Control Clin Trials, vol.17, issue.4, pp.343-349, 1996.

T. Keegan, L. A. Mcclure, J. M. Foran, and C. A. Clarke, Improvements in Survival After Follicular Lymphoma by Race/Ethnicity and Socioeconomic Status: A Population-Based Study, J Clin Oncol, vol.27, issue.18, pp.3044-51, 2009.

K. R. Carson, N. L. Bartlett, J. R. Mcdonald, S. Luo, A. Zeringue et al., Increased Body Mass Index Is Associated With Improved Survival in United States Veterans With Diffuse Large B-Cell Lymphoma, J Clin Oncol, vol.30, issue.26, p.3217, 2012.

X. Han, J. Stevens, and P. T. Bradshaw, Body mass index, weight change and survival in non-Hodgkin lymphoma patients in Connecticut women, Nutr Cancer, vol.65, issue.1, pp.43-50, 2013.

T. Li, Z. Liu, P. Liang, and H. Wang, Can body mass index predict the outcome of diffuse large B-cell lymphoma? A single-center retrospective study in China, Leuk Lymphoma, vol.3, issue.7, pp.1624-1633, 2017.

E. Giovannucci, The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control CCC, vol.16, pp.83-95, 2005.

J. G. Haddad and T. J. Hahn, Natural and synthetic sources of circulating 25-hydroxyvitamin D in man, Nature, vol.244, issue.5417, pp.515-522, 1973.

M. T. Drake, M. J. Maurer, B. K. Link, T. M. Habermann, S. M. Ansell et al., Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma, J Clin Oncol Off J Am Soc Clin Oncol, vol.28, issue.27, pp.4191-4199, 2010.

J. L. Kelly, G. Salles, B. Goldman, R. I. Fisher, P. Brice et al., Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies, J Clin Oncol, vol.33, issue.13, pp.1482-90, 2015.

N. J. Ollberding, A. M. Evens, B. Aschebrook-kilfoy, D. Caces, D. D. Weisenburger et al., PreDiagnosis Cigarette Smoking and Overall Survival in Non-Hodgkin Lymphoma, Br J Haematol, vol.163, issue.3, pp.352-358, 2013.

L. E. Diaz, A. Montero, M. González-gross, A. I. Vallejo, J. Romeo et al., Influence of alcohol consumption on immunological status: a review, Eur J Clin Nutr, vol.56, issue.3, pp.50-53, 2002.

G. Szabo and B. Saha, Alcohol's Effect on Host Defense, Alcohol Res Curr Rev, vol.37, issue.2, pp.159-70, 2015.

H. Dong, L. Zhou, C. Fang, L. Fan, D. Zhu et al., TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage, Med Oncol Northwood Lond Engl, vol.29, issue.3, pp.2166-73, 2012.

N. S. Andersen, M. K. Jensen, P. De-nully-brown, and C. H. Geisler, A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors, Eur J Cancer Oxf Engl, vol.38, issue.3, pp.401-409, 1990.

A. Abrahamsson, A. Albertsson-lindblad, P. N. Brown, S. Baumgartner-wennerholm, L. M. Pedersen et al., Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study, Blood, vol.124, issue.8, pp.1288-95, 2014.

C. Leux, M. Maynadié, X. Troussard, Q. Cabrera, A. Herry et al., Mantle cell lymphoma epidemiology: a population-based study in France, Ann Hematol, vol.93, issue.8, pp.1327-1360, 2014.

S. , L. Guyader-peyrou, A. Belot, M. Maynadié, F. Binder-foucard et al., Cancer incidence in France over the 1980-2012 period : Hematological malignancies, Rev Epidemiol Sante Publique, vol.64, issue.2, pp.103-112, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01511580

A. Monnereau, L. Remontet, M. Maynadié, F. Binder-foucard, A. Belot et al., Estimation nationale de l'incidence des cancers en

F. Entre, , 1980.

R. Küppers, Mechanisms of B-cell lymphoma pathogenesis, Nat. Rev. Cancer, vol.5, issue.4, pp.251-262, 2005.

H. Steven, E. Swerdlow, S. A. Campo, N. L. Pileri, H. Harris et al.,

. Jaffe, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol.127, issue.20, pp.2375-2390, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01800015

J. O. Armitage, Staging non-Hodgkin lymphoma, CA Cancer J Clin, vol.55, issue.6, pp.368-376, 2005.

N. L. Harris, E. S. Jaffe, J. Diebold, G. Flandrin, H. K. Muller-hermelink et al., Lymphoma classification-from controversy to consensus : the R.E.A.L. and WHO Classification of lymphoid neoplasms, Ann. Oncol, vol.11, pp.3-10, 2000.

E. Campo, S. H. Swerdlow, N. L. Harris, S. Pileri, H. Stein et al.,

. Jaffe and . The, WHO classification of lymphoid neoplasms and beyond : evolving concepts and practical applications, Blood, vol.117, issue.19, pp.5019-5032, 2008.

A. Belot, P. Grosclaude, N. Bossard, E. Jougla, E. Benhamou et al., Cancer incidence and mortality in France over the period, vol.56, pp.159-175, 1980.
URL : https://hal.archives-ouvertes.fr/hal-00538673

J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers et al., Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer, vol.136, issue.5, pp.359-386, 2015.

D. , M. Parkin, F. Bray, J. Ferlay, and P. Pisani, Global cancer statistics, CA Cancer J Clin, vol.55, issue.2, pp.74-108, 2002.

J. Ferlay, E. Steliarova-foucher, J. Lortet-tieulent, S. Rosso, J. W. Coebergh et al., Cancer incidence and mortality patterns in Europe : estimates for 40 countries in 2012, Eur. J. Cancer, vol.49, issue.6, pp.1374-1403, 2013.

D. Dominik, P. J. Alexander, . Mink, . Hans-olov, E. T. Adami et al.,

D. Mandel and . Trichopoulos, The non-Hodgkin lymphomas : A review of the epidemiologic literature, Int. J. Cancer, vol.120, issue.S12, pp.1-39, 2007.

A. Monnereau, Z. Uhry, N. Bossard, A. Cowppli-bony, N. Voirin et al., Survie des personnes atteintes de cancer en France métropolitaine 1989-2013 -Partie 2 : hémopathies malignes, 2016.

C. Bray, D. S. Morrison, and P. Mckay, Socio-economic deprivation and survival of non-Hodgkin lymphoma in Scotland, Leukemia & Lymphoma, vol.49, issue.5, pp.917-923, 2008.

B. L. Frederiksen, S. O. Dalton, M. Osler, M. Steding-jessen, and P. De-nully-brown, Socioeconomic position, treatment, and survival of non-Hodgkin lymphoma in Denmark -a nationwide study, British Journal of Cancer, vol.106, issue.5, p.988, 2012.

P. Birgitte-lidegaard-frederiksen, . De-nully, S. O. Brown, M. Dalton, M. Steding-jessen et al., Socioeconomic inequalities in prognostic markers of nonHodgkin lymphoma : Analysis of a national clinical database, European Journal of Cancer, vol.47, issue.6, pp.910-917, 2011.

J. F. Simard, F. Baecklund, E. T. Chang, E. Baecklund, H. Hjalgrim et al., Lifestyle factors, autoimmune disease and family history in prognosis of non-hodgkin lymphoma overall and subtypes, Int. J. Cancer, vol.132, issue.11, pp.2659-2666, 2013.

S. M. Geyer, L. M. Morton, T. M. Habermann, C. Allmer, S. Davis et al., Smoking, Alcohol Use, Obesity, and Overall Survival from Non-Hodgkin Lymphoma : A Population-Based Study, Cancer, vol.116, issue.12, pp.2993-3000, 2010.

N. J. Ollberding, A. M. Evens, B. Aschebrook-kilfoy, D. Bennett, D. Caces et al., Pre-Diagnosis Cigarette Smoking and Overall Survival in Non-Hodgkin Lymphoma, Br J Haematol, vol.163, issue.3, pp.352-356, 2013.

J. Ji, X. Liu, K. Sundquist, and J. Sundquist, Survival of cancer in patients with rheumatoid arthritis : a follow-up study in Sweden of patients hospitalized with rheumatoid arthritis 1 year before diagnosis of cancer, Rheumatology (Oxford), vol.50, issue.8, pp.1513-1518, 2011.

T. R. Mikuls, J. O. Endo, S. E. Puumala, P. A. Aoun, N. A. Black et al., Prospective study of survival outcomes in Non-Hodgkin's lymphoma patients with rheumatoid arthritis, J. Clin. Oncol, vol.24, issue.10, pp.1597-1602, 2006.

C. Tseng, Diabetes, insulin use, and non-Hodgkin lymphoma mortality in Taiwan, Metabolism, issue.7, pp.1003-1009, 2012.

I. H. Langford, G. Bentham, and A. Mcdonald, Mortality from non-Hodgkin lymphoma and UV exposure in the, European Community. Health & Place, vol.4, issue.4, pp.355-364, 1998.

A. C. Pesatori, D. Consonni, M. Rubagotti, P. Grillo, and P. A. Bertazzi, Cancer incidence in the population exposed to dioxin after the "Seveso accident" : twenty years of follow-up, Environ Health, vol.8, p.39, 2009.

A. Cecilia-pesatori, P. Grillo, D. Consonni, M. Caironi, G. Sampietro et al., Update of the mortality study of workers exposed to polychlorinated biphenyls (Pcbs) in two Italian capacitor manufacturing plants, Med Lav, vol.104, issue.2, pp.107-114, 2013.

T. Battaglioli, G. Gorini, A. Costantini, P. Crosignani, L. Miligi et al., Cigarette smoking and alcohol consumption as determinants of survival in non-Hodgkin's lymphoma : a population-based study, Ann. Oncol, vol.17, issue.8, pp.1283-1289, 2006.

K. R. Carson, N. L. Bartlett, J. R. Mcdonald, S. Luo, A. Zeringue et al., Increased Body Mass Index Is Associated With Improved Survival in United States Veterans With Diffuse Large B-Cell Lymphoma, Journal of Clinical Oncology, vol.30, issue.26, p.3217, 2012.

X. Han, T. Zheng, F. M. Foss, S. Ma, T. R. Holford et al., Alcohol consumption and non-Hodgkin lymphoma survival, J Cancer Surviv, vol.4, issue.2, pp.101-109, 2010.
URL : https://hal.archives-ouvertes.fr/hal-01260433

J. A. Jones, L. E. Fayad, L. S. Elting, and M. A. Rodriguez, Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma, Leukemia & Lymphoma, vol.51, issue.9, pp.1649-1657, 2010.

R. Talamini, J. Polesel, M. Spina, E. Chimienti, D. Serraino et al., The impact of tobacco smoking and alcohol drinking on survival of patients with non-Hodgkin lymphoma, Int. J. Cancer, vol.122, issue.7, pp.1624-1629, 2008.

K. E. Smedby and H. Hjalgrim, Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes, Seminars in Cancer Biology, vol.21, issue.5, pp.293-298, 2011.

H. Rappaport, New concepts in the classification of malignant hemopathies, Bull Cancer, vol.61, issue.1, pp.11-22, 1974.

K. Lennert, R. D. Collins, and R. J. Lukes, Concordance of the Kiel and Lukes-Collins classifications of non-Hodgkin's lymphomas, Histopathology, vol.7, issue.4, pp.549-559, 1983.

, National cancer institute sponsored study of classifications of non-hodgkin's lymphomas. Summary and description of a working formulation for clinical usage, Cancer, vol.49, issue.10, pp.2112-2135, 1982.

A. G. Stansfeld, J. Diebold, H. Noel, Y. Kapanci, F. Rilke et al.,

, Lancet, vol.1, issue.8580, pp.292-293, 1988.

N. L. Harris, E. S. Jaffe, J. Diebold, G. Flandrin, H. K. Mullerhermelink et al., World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues : Report of the Clinical Advisory Committee Meeting-Airlie House, Journal of Clinical Oncology, vol.17, issue.12, pp.3835-3849, 1997.

E. S. Jaffe, N. L. Harris, J. Diebold, and H. K. Müller-hermelink, World Health Organization Classification of lymphomas : a work in progress, Ann. Oncol, vol.9, pp.25-30, 1998.

G. Salles, Les lymphomes malins, hodgkiniens et non hodgkiniens, 2011.

M. Stephen, J. Ansell, and . Armitage, Non-Hodgkin lymphoma : diagnosis and treatment

, Mayo Clin. Proc, vol.80, issue.8, pp.1087-1097, 2005.

P. Solal-celigny, N. Brousse, C. Fermé, C. Gisselbrecht, B. Coiffier et al., Lymphomes non hodgkiniens, Maladie de Hodgkin (3e édition), 1997.

J. J. Sotto and R. Gressin, Les lymphomes malins non hodgkiniens (164a).pdf, 2005.

S. A. Rosenberg, Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas, Cancer Treat Rep, vol.61, issue.6, pp.1023-1027, 1977.

T. A. Lister, D. Crowther, S. B. Sutcliffe, E. Glatstein, G. P. Canellos et al., Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease : Cotswolds meeting, J. Clin. Oncol, vol.7, issue.11, pp.1630-1636, 1989.

P. Adamson, F. Bray, A. S. Costantini, M. Tao, E. Weiderpass et al., Time trends in the registration of Hodgkin and non-Hodgkin lymphomas in Europe, Eur. J. Cancer, vol.43, issue.2, pp.391-401, 2007.

P. Hartge and S. S. Devesa, Quantification of the impact of known risk factors on time trends in non-Hodgkin's lymphoma incidence, Cancer Res, vol.52, pp.5566-5569, 1992.

M. Sant, C. Allemani, C. Tereanu, R. D. Angelis, R. Capocaccia et al., Incidence of hematologic malignancies in Europe by morphologic subtype : results of the HAEMACARE project, Blood, vol.116, issue.19, pp.3724-3734, 2010.

N. Becker, J. Fortuny, T. Alvaro, A. Nieters, M. Maynadié et al., Medical history and risk of lymphoma : results of a

, J. Cancer Res. Clin. Oncol, vol.135, issue.8, pp.1099-1107, 2009.

P. Boffetta, B. Armstrong, M. Linet, C. Kasten, W. Cozen et al., Consortia in Cancer Epidemiology : Lessons from InterLymph, Cancer Epidemiol Biomarkers Prev, vol.16, issue.2, pp.197-199, 2007.

E. A. Holly and C. Lele, Non-Hodgkin's lymphoma in HIV-positive and HIV-negative homosexual men in the San Francisco Bay Area : allergies, prior medication use, and sexual practices

, J. Acquir. Immune Defic. Syndr. Hum. Retrovirol, vol.15, issue.3, pp.211-222, 1997.

E. Baecklund, A. Ekbom, P. Sparén, N. Feltelius, and L. Klareskog, Disease activity and risk of lymphoma in patients with rheumatoid arthritis : nested case-control study, BMJ, vol.317, issue.7152, pp.180-181, 1998.

J. Fortuny, Y. Benavente, R. Bosch, M. García-villanueva, A. Fernán-dez-de-sevilla et al., Type 2 diabetes mellitus, its treatment and risk for lymphoma, Eur. J. Cancer, vol.41, issue.12, pp.1782-1787, 2005.

Y. Zhang, T. R. Holford, B. Leaderer, P. Boyle, S. H. Zahm et al., Blood transfusion and risk of non-Hodgkin's lymphoma in Connecticut women, Am. J. Epidemiol, vol.160, issue.4, pp.325-330, 2004.

J. L. Hsu and S. L. Glaser, Epstein-barr virus-associated malignancies : epidemiologic patterns and etiologic implications, Crit. Rev. Oncol. Hematol, vol.34, issue.1, pp.27-53, 2000.

N. Becker, P. Schnitzler, P. Boffetta, P. Brennan, L. Foretova et al., Hepatitis B virus infection and risk of lymphoma : results of a serological analysis within the European case-control study Epilymph, J. Cancer Res. Clin. Oncol, vol.138, issue.12, pp.1993-2001, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01262992

P. Cocco, G. Piras, M. Monne, A. Uras, A. Gabbas et al., Risk of malignant lymphoma following viral hepatitis infection, Int J Hematol, vol.87, issue.5, pp.474-483, 2008.

Y. Jee-hyun-kim, B. Bang, T. Park, C. Yoo, T. Kim et al., Hepatitis B virus infection and B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area : a case-control study, Jpn. J. Cancer Res, vol.93, issue.5, pp.471-477, 2002.

C. Mazzaro, V. Zagonel, S. Monfardini, P. Tulissi, E. Pussini et al., Hepatitis C virus and non-Hodgkin's lymphomas, Br. J. Haematol, vol.94, issue.3, pp.544-550, 1996.

A. Nieters, B. Kallinowski, P. Brennan, M. Ott, M. Maynadié et al.,

P. Whitby, N. Boffetta, S. Becker, and . Sanjosé, Hepatitis C and risk of lymphoma : results of the European multicenter case-control study EPILYMPH, Gastroenterology, vol.131, issue.6, pp.1879-1886, 2006.

R. Talamini, M. Montella, M. Crovatto, L. Dal-maso, A. Crispo et al., Non-Hodgkin's lymphoma and hepatitis C virus : A case-control study from northern and southern Italy

, J. Cancer, vol.110, issue.3, pp.380-385, 2004.

F. Wang, R. Xu, B. Han, Y. Shi, H. Luo et al., High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers, Cancer, vol.109, issue.7, pp.1360-1364, 2007.

P. Cocco, A. Mannetje, D. Fadda, M. Melis, N. Becker et al., Occupational exposure to solvents and risk of lymphoma subtypes : results from the Epilymph case-control study, Occup Environ Med, vol.67, issue.5, pp.341-347, 2010.
URL : https://hal.archives-ouvertes.fr/hal-01260431

P. Cocco,

, G Ital Med Lav Ergon, vol.25, issue.3, pp.420-421, 2003.

P. Cocco, G. Satta, D. Ileana, T. Andrea, G. Nonne et al., Ennas, and Paolo Boffetta. Lymphoma risk in livestock farmers : results of the Epilymph study, Int. J. Cancer, vol.132, issue.11, pp.2613-2618, 2013.

L. Costas, C. Infante-rivard, J. Zock, M. Van-tongeren, P. Boffetta et al., Occupational exposure to endocrine disruptors and lymphoma risk in a multi-centric European study, Br. J. Cancer, vol.112, issue.7, pp.1251-1256, 2015.

M. Merhi, H. Raynal, E. Cahuzac, F. Vinson, J. P. Cravedi et al., Occupational exposure to pesticides and risk of hematopoietic cancers : meta-analysis of case-control studies, Cancer Causes Control, vol.18, issue.10, pp.1209-1226, 2007.

M. B. Cook, K. A. Mcglynn, S. S. Devesa, N. D. Freedman, and W. F. ,

A. , Sex disparities in cancer mortality and survival, Cancer Epidemiol. Biomarkers Prev, vol.20, issue.8, pp.1629-1637, 2011.

M. Hauptmann, J. H. Lubin, P. A. Stewart, R. B. Hayes, and A. Blair, Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries

, J. Natl. Cancer Inst, vol.95, issue.21, pp.1615-1623, 2003.

S. L. Slager, Y. Benavente, A. Blair, R. Vermeulen, J. R. Cerhan et al.,

D. Sampson, P. Casabonne, S. Cocco, and . De-sanjosé, Medical History, Lifestyle, Family History, and Occupational Risk Factors for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma : The InterLymph Non-Hodgkin Lymphoma Subtypes Project, J Natl Cancer Inst Monogr, issue.48, pp.41-51, 2014.

M. S. Linet, C. M. Vajdic, L. M. Morton, A. J. De-roos, and C. F. ,

P. Skibola, J. R. Boffetta, C. R. Cerhan, . Flowers, A. Silvia-de-sanjosé et al., Medical History, Lifestyle, Family History, and Occupational Risk Factors for Follicular Lymphoma : The InterLymph Non-Hodgkin Lymphoma Subtypes Project, J Natl Cancer Inst Monogr, issue.48, pp.26-40, 2014.

J. R. Cerhan, A. Kricker, O. Paltiel, C. R. Flowers, S. S. Wang et al.,

L. Foran, J. Miligi, L. Clavel, N. Bernstein, S. L. Rothman et al., Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma : the InterLymph Non-Hodgkin Lymphoma Subtypes Project, J. Natl. Cancer Inst. Monographs, issue.48, pp.15-25, 2014.

N. C. Briggs, R. S. Levine, and E. A. Brann, Allergies and risk of nonHodgkin's lymphoma by subtype, Cancer Epidemiol. Biomarkers Prev, vol.11, issue.4, pp.401-407, 2002.

P. M. Bracci, Y. Benavente, J. J. Turner, O. Paltiel, S. L. Slager et al., Ahmet Dogan

M. Smedby, J. J. Maynadié, E. Spinelli, B. Roman, S. S. Glimelius et al., Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma : the InterLymph Non-Hodgkin Lymphoma Subtypes Project, J. Natl. Cancer Inst. Monographs, issue.48, pp.52-65, 2014.

E. T. Chang, T. Zheng, E. G. Weir, M. Borowitz, R. B. Mann et al., Childhood social environment and Hodgkin's lymphoma : new findings from a population-based case-control study, Cancer Epidemiol. Biomarkers Prev, vol.13, issue.8, pp.1361-1370, 2004.

P. Vineis, L. Miligi, P. Crosignani, A. Fontana, G. Masala et al., Delayed infection, family size and malignant lymphomas, J Epidemiol Community Health, vol.54, issue.12, pp.907-911, 2000.

S. S. Wang, S. L. Slager, P. Brennan, E. A. Holly, S. D. Sanjose et al.,

P. L. Chiu, F. Cocco, Y. Mensah, A. Zhang, L. Nieters et al.,

P. M. Bracci, A. S. Costantini, P. Vineis, R. K. Severson, and E. Roman,

N. Foretova, A. Becker, M. Staines, T. Vornanen, P. Zheng et al., Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL) : a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph), Blood, vol.109, issue.8, pp.3479-3488, 2007.

R. Casey, P. Brennan, N. Becker, P. Boffetta, P. Cocco et al.,

M. Vornanen and . Maynadié, Influence of familial cancer history on lymphoid neoplasms risk validated in the large European case-control study epilymph, Eur. J. Cancer, vol.42, issue.15, pp.2570-2576, 2006.

E. T. Chang, T. Frøslev, H. T. Sørensen, and L. Pedersen, A nationwide study of aspirin, other non-steroidal anti-inflammatory drugs, and Hodgkin lymphoma risk in Denmark, Br. J. Cancer, vol.105, issue.11, pp.1776-1782, 2011.

E. A. Holly and P. M. Bracci, Population-based study of non-Hodgkin lymphoma, histology, and medical history among human immunodeficiency virus-negative participants in San Francisco, Am. J. Epidemiol, vol.158, issue.4, pp.316-327, 2003.

Y. Zhang, T. R. Holford, B. Leaderer, S. H. Zahm, P. Boyle et al.,

T. Owens and . Zheng, Prior medical conditions and medication use and risk of nonHodgkin lymphoma in Connecticut United States women, Cancer Causes Control, vol.15, issue.4, pp.419-428, 2004.

E. T. Chang, H. Hjalgrim, K. E. Smedby, M. Akerman, E. Tani et al., Body mass index and risk of malignant lymphoma in Scandinavian men and women, J. Natl. Cancer Inst, vol.97, issue.3, pp.210-218, 2005.

Y. Benavente, N. Garcia, E. Domingo-domenech, T. Alvaro, R. Font et al., Regular use of hair dyes and risk of lymphoma in Spain

, Int J Epidemiol, vol.34, issue.5, pp.1118-1122, 2005.

G. H. Rauscher, D. Shore, and D. P. Sandler, Hair dye use and risk of adult acute leukemia, Am. J. Epidemiol, vol.160, issue.1, pp.19-25, 2004.

A. Tavani, E. Negri, S. Franceschi, R. Talamini, D. Serraino et al., Hair dye use and risk of lymphoid neoplasms and soft tissue sarcomas, Int. J. Cancer, vol.113, issue.4, pp.629-631, 2005.

Y. Zhang, T. R. Holford, B. Leaderer, P. Boyle, S. H. Zahm et al., Hair-coloring product use and risk of non-Hodgkin's lymphoma : a population-based case-control study in Connecticut

, Am. J. Epidemiol, vol.159, issue.2, pp.148-154, 2004.

R. Cartwright, R. Mcnally, and A. Staines, The increasing incidence of non-Hodgkin's lymphoma (NHL) : the possible role of sunlight, Leuk. Lymphoma, vol.14, issue.5-6, pp.387-394, 1994.

M. Melbye, H. O. Adami, H. Hjalgrim, and B. Glimelius, Ultraviolet light and non-Hodgkin's lymphoma, Acta Oncol, vol.35, issue.6, pp.655-657, 1996.

R. Casey, K. Piazzon-fevre, N. Raverdy, M. Forzy, B. Tretare et al., Case-control study of lymphoid neoplasm in three French areas : description, alcohol and tobacco consumption, Eur. J. Cancer Prev, vol.16, issue.2, pp.142-150, 2007.

M. Paige, E. A. Bracci, and . Holly, Tobacco use and non-Hodgkin lymphoma : results from a population-based case-control study in the San Francisco Bay Area, California. Cancer Causes Control, vol.16, issue.4, pp.333-346, 2005.

M. Kamper-jørgensen, K. Rostgaard, S. L. Glaser, S. H. Zahm, W. Cozen et al., Cigarette smoking and risk of Hodgkin lymphoma and its subtypes : a pooled analysis from the International Lymphoma Epidemiology Consortium (InterLymph), Ann. Oncol, vol.24, issue.9, pp.2245-2255, 2013.

L. M. Morton, P. Hartge, T. R. Holford, and E. A. Holly,

P. Chiu, E. Vineis, E. V. Stagnaro, S. Willett, C. L. Franceschi et al.,

F. R. Mayne, J. R. Dee, T. Cerhan, and . Zheng, Cigarette smoking and risk of non-Hodgkin lymphoma : a pooled analysis from the International Lymphoma Epidemiology Consortium (interlymph), Cancer Epidemiol. Biomarkers Prev, vol.14, issue.4, pp.925-933, 2005.

, International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma, N. Engl. J. Med, vol.329, issue.14, pp.987-994, 1993.

P. Solal-céligny, P. Roy, P. Colombat, J. White, J. O. Armitage et al.,

E. Coiffier, C. Conde-garcia, M. Doyen, R. I. Federico, and J. F. Fisher,

C. Garcia-conde, A. Guglielmi, C. Hagenbeek, M. Haïoun, A. T. Leblanc et al.,

U. Tilly, P. Vitolo, E. Zinzani, E. Zucca, and . Montserrat, Follicular lymphoma international prognostic index, Blood, vol.104, issue.5, pp.1258-1265, 2004.
URL : https://hal.archives-ouvertes.fr/hal-00427653

S. Linda, . Evans, W. Barry, and . Hancock, Non-Hodgkin lymphoma, The Lancet, vol.362, issue.9378, pp.139-146, 2003.

S. Yuda, D. Maruyama, A. M. Maeshima, S. Makita, H. Kitahara et al., Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era, Ann. Hematol, vol.95, issue.12, pp.2017-2022, 2016.

R. I. Fisher, E. R. Gaynor, S. Dahlberg, M. M. Oken, T. M. Grogan et al., Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma, N. Engl. J. Med, vol.328, issue.14, pp.1002-1006, 1993.

B. Coiffier, E. Lepage, J. Briere, R. Herbrecht, H. Tilly et al., CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, N. Engl. J. Med, vol.346, issue.4, pp.235-242, 2002.

J. Antonio and . Grillo-lópez, Rituximab (Rituxan/MabThera) : the first decade, vol.3, pp.767-779, 1993.

M. R. Smith, Rituximab (monoclonal anti-CD20 antibody) : mechanisms of action and resistance, Oncogene, vol.22, issue.47, pp.7359-7368, 2003.

J. D. Hainsworth, S. Litchy, D. W. Shaffer, V. L. Lackey, M. Grimaldi et al., Maximizing Therapeutic Benefit of Rituximab : Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin's Lymphoma-A Randomized Phase II Trial of the Minnie Pearl Cancer Research Network, JCO, vol.23, issue.6, pp.1088-1095, 2005.

P. Colombat, G. Salles, N. Brousse, P. Eftekhari, P. Soubeyran et al., Astasia Stamatoullas

. Céligny, Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden : clinical and molecular evaluation, Blood, vol.97, issue.1, pp.101-106, 2001.

R. Forstpointner, M. Unterhalt, M. Dreyling, H. Böck, R. Repp et al., Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas : Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG), Blood, vol.108, issue.13, pp.4003-4008, 2006.

M. Ghielmini, K. Rufibach, G. Salles, L. Leoncini-franscini, C. Léger-falandry et al., Single agent rituximab in patients with follicular or mantle cell lymphoma : clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system : a study of the Swiss Group for Clinical Cancer Research (SAKK), Ann. Oncol, vol.16, issue.10, pp.1675-1682, 2005.

W. Hiddemann and M. Dreyling, Mantle cell lymphoma : therapeutic strategies are different from CLL, Curr Treat Options Oncol, vol.4, issue.3, pp.219-226, 2003.

L. Vidal, A. Gafter-gvili, G. Salles, S. Bousseta, B. Oberman et al., Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis, European Journal of Cancer, vol.76, pp.216-225, 2017.

T. M. Habermann, E. A. Weller, V. A. Morrison, R. D. Gascoyne, and A. Peter,

J. B. Cassileth, . Cohn, R. Shaker, B. Dakhil, R. I. Woda et al., Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma, J. Clin. Oncol, vol.24, issue.19, pp.3121-3127, 2006.

R. Thomas, C. W. Callihan, and . Berard, The classification and pathology of the lymphomas and leukemias, Seminars in Roentgenology, vol.15, issue.3, pp.203-218, 1980.

D. D. Weisenburger, H. Kim, and H. Rappaport, Mantle-zone lymphoma : a follicular variant of intermediate lymphocytic lymphoma, Cancer, vol.49, issue.7, pp.1429-1438, 1982.

N. L. Harris, E. S. Jaffe, H. Stein, P. M. Banks, J. K. Chan et al., A revised European-American classification of lymphoid neoplasms : a proposal from the International Lymphoma Study Group, Blood, vol.84, issue.5, pp.1361-1392, 1994.

M. Dandoit, M. Mounier, J. Guy, T. Petrella, S. Girard et al., The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French populationbased registry, Leuk. Lymphoma, vol.56, issue.4, pp.1050-1057, 2015.

F. Bertoni and M. Ponzoni, The cellular origin of mantle cell lymphoma, The International Journal of Biochemistry & Cell Biology, vol.39, issue.10, pp.1747-1753, 2007.

M. Bernard, R. Gressin, F. Lefrère, B. Drénou, B. Branger et al., Blastic variant of mantle cell lymphoma : a rare but highly aggressive subtype, Leukemia, vol.15, issue.11, pp.1785-1791, 2001.

R. Oinonen, K. Franssila, L. Teerenhovi, K. Lappalainen, and E. Elonen, Mantle cell lymphoma : clinical features, treatment and prognosis of 94 patients, European Journal of Cancer, vol.34, issue.3, pp.329-336, 1998.

D. D. Weisenburger and J. O. Armitage, Mantle cell lymphoma-an entity comes of age, Blood, vol.87, issue.11, pp.4483-4494, 1996.

L. H. Argatoff, J. M. Connors, R. J. Klasa, D. E. Horsman, and R. D. Gascoyne, Mantle cell lymphoma : a clinicopathologic study of 80 cases, Blood, vol.89, issue.6, pp.2067-2078, 1997.

F. Bosch, P. Jares, E. Campo, A. Lopez-guillermo, M. A. Piris et al., PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders : a highly specific marker of mantle cell lymphoma, Blood, vol.84, issue.8, pp.2726-2732, 1994.

E. Zucca, E. Roggero, G. Pinotti, E. Pedrinis, C. Cappella et al., Patterns of survival in mantle cell lymphoma, Ann. Oncol, vol.6, issue.3, pp.257-262, 1995.

S. A. Pileri and B. Falini, Mantle cell lymphoma, Haematologica, vol.94, issue.11, pp.1488-1492, 2009.
URL : https://hal.archives-ouvertes.fr/hal-01455529

S. Beà, M. Ribas, J. M. Hernández, F. Bosch, M. Pinyol et al., Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants, Blood, vol.93, issue.12, pp.4365-4374, 1999.

F. Bosch, A. López-guillermo, E. Campo, J. M. Ribera, and E. Conde, Miguel Angel Piris, Teresa Vallespí, Soledad Woessner, and Emilio Montserrat. Mantle cell lymphoma, Cancer, vol.82, issue.3, pp.567-575, 1998.

R. Chandran, S. K. Gardiner, M. Simon, and S. E. Spurgeon, Survival trends in mantle cell lymphoma in the United States over 16 years 1992-2007, Leuk. Lymphoma, vol.53, issue.8, pp.1488-1493, 2012.

P. L. Cohen, P. J. Kurtin, K. A. Donovan, and C. A. Hanson, Bone marrow and peripheral blood involvement in mantle cell lymphoma, Br. J. Haematol, vol.101, issue.2, pp.302-310, 1998.

A. Abrahamsson, N. Dahle, and M. Jerkeman, Marked improvement of overall survival in mantle cell lymphoma : a population based study from the Swedish Lymphoma Registry

, Leuk. Lymphoma, vol.52, issue.10, pp.1929-1935, 2011.

C. Y. Cheah, A. George, E. Giné, A. Chiappella, H. C. Kluin-nelemans et al.,

L. Ritchie, M. E. Arcaini, M. Williams, J. F. Dreyling, and . Seymour, European Mantle Cell Lymphoma Network. Central nervous system involvement in mantle cell lymphoma : clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network

, Ann. Oncol, vol.24, issue.8, pp.2119-2123, 2013.

P. Meusers, M. Engelhard, H. Bartels, T. Binder, H. H. Fülle et al., Multicentre randomized therapeutic trial for advanced centrocytic lymphoma : anthracycline does not improve the prognosis, Hematol Oncol, vol.7, issue.5, pp.365-380, 1989.

D. D. Weisenburger, J. M. Vose, T. C. Greiner, J. C. Lynch, W. C. Chan et al.,

W. G. Dave, J. O. Sanger, and . Armitage, Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group, Am. J. Hematol, vol.64, issue.3, pp.190-196, 2000.

E. Vandenberghe, C. Wolf-peeters, G. Vaughan-hudson, B. Vaughan-hudson, S. Pittaluga et al., The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group, Br. J. Haematol, vol.99, issue.4, pp.842-847, 1997.

I. Teodorovic, S. Pittaluga, J. C. Kluin-nelemans, J. H. Meerwaldt, A. Hagenbeek et al.,

R. Glabbeke, L. Somers, E. M. Bijnens, C. D. Noordijk, and . Peeters, Efficacy of four different regimens in 64 mantle-cell lymphoma cases : clinicopathologic comparison with 498 other nonHodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group, J. Clin. Oncol, vol.13, issue.11, pp.2819-2826, 1995.

J. W. Sweetenham, Stem cell transplantation for mantle cell lymphoma : should it ever be used outside clinical trials ?, Bone Marrow Transplant, vol.28, issue.9, pp.813-820, 2001.

E. Zucca, H. Stein, and B. Coiffier, European Lymphoma Task Force (ELTF) : Report of the workshop on Mantle Cell Lymphoma (MCL), Ann. Oncol, vol.5, issue.6, pp.507-511, 1994.

G. Lenz, M. Dreyling, E. Hoster, B. Wörmann, U. Dührsen et al.,

E. Martin, A. Heidemann, R. Aldaoud, J. Parwaresch, M. Hasford et al., Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma : results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG), J. Clin. Oncol, vol.23, issue.9, pp.1984-1992, 2005.

H. Christian, A. Geisler, A. Kolstad, M. Laurell, R. Jerkeman et al., Erkki Elonen, and Nordic Lymphoma Group. Nordic MCL2 trial update : six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support : still very long survival but late relapses do occur, Mats Ehinger

, J. Haematol, vol.158, issue.3, pp.355-362, 2012.

R. Gressin, S. Caulet-maugendre, E. Deconinck, O. Tournilhac, E. Gyan et al., Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group, Haematologica, vol.95, issue.8, pp.1350-1357, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00508037

R. Oinonen, E. Jantunen, M. Itälä, T. Lehtinen, O. Kuittinen et al., Autologous stem cell transplantation in patients with mantle cell lymphoma, Leuk. Lymphoma, vol.43, issue.6, pp.1229-1237, 2002.

N. S. Andersen, M. K. Jensen, P. De-nully-brown, and C. H. Geisler, A Danish populationbased analysis of 105 mantle cell lymphoma patients : incidences, clinical features, response, survival and prognostic factors, Eur. J. Cancer, vol.38, issue.3, pp.401-408, 2002.

J. M. Vose, Mantle cell lymphoma : 2013 Update on diagnosis, risk-stratification, and clinical management, Am. J. Hematol, vol.88, issue.12, pp.1082-1088, 2013.

R. Delarue, C. Haioun, V. Ribrag, P. Brice, A. Delmer et al., Etude des Lymphomes de l'Adulte (GELA). CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma : a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte, Blood, vol.121, issue.1, pp.48-53, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01701871

O. Hermine, E. Hoster, J. Walewski, A. Bosly, S. Stilgenbauer et al., Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger) : a randomised, open-label, Christiane Pott, Wolfgang Hiddemann, Michael Unterhalt, and Martin Dreyling, vol.388, pp.565-575, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01523540

A. M. Gianni, M. Magni, M. Martelli, M. Di-nicola, C. Carlostella et al., Longterm remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen), Blood, vol.102, issue.2, pp.749-755, 2003.

M. Dreyling, G. Lenz, E. Hoster, A. Van-hoof, C. Gisselbrecht et al., Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma : results of a prospective randomized trial of the European MCL Network, Blood, vol.105, issue.7, pp.2677-2684, 2005.

C. Steven-le-gouill, L. Thieblemont, A. Oberic, K. Moreau, E. Bouabdallah et al., Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma

. Lysa/goelams and . Group, Blood, vol.128, issue.22, pp.145-145, 2016.

M. Vignon, M. Venon, O. Hermine, and R. Delarue, Management of mantle cell lymphoma in the elderly : current and potential strategies, Drugs Aging, vol.30, issue.12, pp.979-986, 2013.

H. C. Kluin-nelemans, E. Hoster, O. Hermine, J. Walewski, M. Trneny et al.,

, J. Med, vol.367, issue.6, pp.520-531, 2012.

C. Visco, A. Chiappella, L. Nassi, C. Patti, S. Ferrero et al., Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma : a multicentre, phase 2 trial from Fondazione Italiana Linfomi, The Lancet Haematology, vol.4, issue.1, pp.15-23, 2017.

A. Abrahamsson, A. Albertsson-lindblad, P. N. Brown, S. Baumgartnerwennerholm, L. M. Pedersen et al., Real world data on primary treatment for mantle cell lymphoma : a Nordic Lymphoma Group observational study, Blood, vol.124, issue.8, pp.1288-1295, 2014.

J. F. Chan-yoon-cheah, M. L. Seymour, and . Wang, Mantle Cell Lymphoma, J. Clin. Oncol, vol.34, issue.11, pp.1256-1269, 2016.

M. Dreyling and S. Ferrero, and European Mantle Cell Lymphoma Network. The role of targeted treatment in mantle cell lymphoma : is transplant dead or alive ?, Haematologica, vol.101, issue.2, pp.104-114, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01455529

B. S. Kahl, M. Dreyling, L. I. Gordon, L. Quintanilla-martinez, and E. M. ,

. Sotomayor, Recent advances and future directions in mantle cell lymphoma research : report of the 2016 mantle cell lymphoma consortium workshop, Leuk. Lymphoma, vol.58, issue.7, pp.1561-1569, 2017.

B. G. Till, H. Li, S. H. Bernstein, R. I. Fisher, W. R. Burack et al.,

M. Smith, J. W. Leblanc, and . Friedberg, Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma : SWOG S0601, Br. J. Haematol, vol.172, issue.2, pp.208-218, 2016.

M. Rummel, U. Kaiser, C. Balser, M. Stauch, W. Brugger et al.,

, Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas : a multicentre, randomised, open-label, non-inferiority phase 3 trial, Lancet Oncol, vol.17, issue.1, pp.57-66, 2016.

N. Vallumsetla, J. Paludo, and P. Kapoor, Bortezomib in mantle cell lymphoma : comparative therapeutic outcomes, Ther Clin Risk Manag, vol.11, pp.1663-1674, 2015.

P. Mondello, N. Steiner, W. Willenbacher, C. Arrigo, S. Cuzzocrea et al., 90y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation : Is It Time for a Step Forward, Clin Lymphoma Myeloma Leuk, vol.16, issue.2, pp.82-88, 2016.

T. Robak, Novel therapies under investigation for mantle cell lymphoma, Expert Opinion on Investigational Drugs, vol.25, issue.4, pp.375-380, 2016.

D. Chiron, C. Bellanger, A. Papin, C. Benoit-tessoulin, S. Dousset et al., and Catherine Pellat-Deceunynck. Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma, Blood, vol.128, issue.24, pp.2808-2818, 2016.

H. Zhu and A. Almasan, Development of venetoclax for therapy of lymphoid malignancies, Drug Des Devel Ther, vol.11, pp.685-694, 2017.

E. Hoster, M. Dreyling, W. Klapper, C. Gisselbrecht, . Achiel-van-hoof et al., Michael Unterhalt, German Low Grade Lymphoma Study Group (GLSG), and European Mantle Cell Lymphoma Network. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma, Blood, vol.111, issue.2, pp.558-565, 2008.

E. Hoster, W. Klapper, O. Hermine, C. Hanneke, J. Kluin-nelemans et al., Dreyling, and Michael Unterhalt. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network, J. Clin. Oncol, vol.32, issue.13, pp.1338-1346, 2014.

M. A. Shipp, Identification of Major Prognostic Subgroups of Patients with Large-Cell Lymphoma Treated with m-BACOD or M-BACOD, Annals of Internal Medicine, vol.104, issue.6, p.757, 1986.

H. Samaha, C. Dumontet, N. Ketterer, I. Moullet, C. Thieblemont et al., Mantle cell lymphoma : a retrospective study of 121 cases, Leukemia, vol.12, issue.8, pp.1281-1287, 1998.

T. C. Greiner, M. J. Moynihan, W. C. Chan, D. M. Lytle, A. Pedersen et al., p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis, Blood, vol.87, issue.10, pp.4302-4310, 1996.

L. Hernandez, T. Fest, M. Cazorla, J. Teruya-feldstein, F. Bosch et al., p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas, Blood, vol.87, issue.8, pp.3351-3359, 1996.

H. Dong, L. Zhou, C. Fang, L. Fan, D. Zhu et al., TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage, Med. Oncol, vol.29, issue.3, pp.2166-2173, 2012.

S. Shin, J. Roh, H. J. Cha, Y. Choi, J. Kim et al., TCL1 expression predicts overall survival in patients with mantle cell lymphoma, Dok Hyun Yoon, Cheolwon Suh, and Jooryung Huh, 2015.

. Ting-xun, J. Lu, W. Li, and . Xu, The role of SOX11 in mantle cell lymphoma, Leuk. Res, vol.37, issue.11, pp.1412-1419, 2013.

L. Nordström, S. Sernbo, P. Eden, K. Grønbaek, A. Kolstad et al., Mats Ehinger, Mats Jerkeman, and Sara Ek. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma-a Nordic Lymphoma Group study, Br. J. Haematol, vol.166, issue.1, pp.98-108, 2014.

L. Nygren, S. Baumgartner-wennerholm, M. Klimkowska, B. Christensson, E. Kimby et al., Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma, Blood, vol.119, issue.18, pp.4215-4223, 2012.

A. J. Norton, J. Matthews, V. Pappa, J. Shamash, S. Love et al., Mantle cell lymphoma : natural history defined in a serially biopsied population over a 20-year period, Ann. Oncol, vol.6, issue.3, pp.249-256, 1995.

C. Leux, M. Maynadié, X. Troussard, Q. Cabrera, A. Herry et al., Mantle cell lymphoma epidemiology : a population-based study in France, Ann. Hematol, vol.93, issue.8, pp.1327-1333, 2014.

D. Chihara, N. Asano, K. Ohmachi, T. Kinoshita, M. Okamoto et al., Prognostic model for mantle cell lymphoma in the rituximab era : a nationwide study in Japan, Br. J. Haematol, vol.170, issue.5, pp.657-668, 2015.

P. W. Dickman and H. Adami, Interpreting trends in cancer patient survival, J. Intern. Med, vol.260, issue.2, pp.103-117, 2006.

J. Faivre, J. L. Legoux, F. Martin, R. Michiels, F. Cabanne et al., Incidence of large bowel cancer in, vol.19, pp.221-227, 1979.
URL : https://hal.archives-ouvertes.fr/hal-00698066

F. Binder-foucard, N. Bossard, P. Delafosse, A. Belot, A. Woronoff et al., Remontet, and French network of cancer registries (Francim). Cancer incidence and mortality in France over the 1980-2012 period : solid tumors, Rev Epidemiol Sante Publique, vol.62, issue.2, pp.95-108, 2014.

J. Berkson and R. P. Gage, Calculation of survival rates for cancer, Proc Staff Meet Mayo Clin, vol.25, issue.11, pp.270-286, 1950.

C. Danieli, L. Remontet, N. Bossard, L. Roche, and A. Belot, Estimating net survival : the importance of allowing for informative censoring, Stat Med, vol.31, issue.8, pp.775-786, 2012.

J. Maja-pohar-perme, J. Stare, and . Estève, On estimation in relative survival, Biometrics, vol.68, issue.1, pp.113-120, 2012.

M. Mounier, N. Bossard, A. Belot, L. Remontet, J. Iwaz et al., Anne-Sophie Woronoff, René-Olivier Casasnovas, Marc Maynadié, Roch Giorgi, and FRANCIM Network and MESURE Working Survival Group. Trends in excess mortality in follicular lymphoma at a population level, Eur. J. Haematol, vol.94, issue.2, pp.120-129, 2015.

N. Graffeo, F. Castell, A. Belot, and R. Giorgi, A log-rank-type test to compare net survival distributions, Biometrics, vol.72, issue.3, pp.760-769, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01218237

C. P. Nelson, P. C. Lambert, I. B. Squire, and D. R. Jones, Flexible parametric models for relative survival, with application in coronary heart disease, Statist. Med, vol.26, issue.30, pp.5486-5498, 2007.

N. S. Andersen, M. K. Jensen, P. De-nully-brown, and C. H. Geisler, A Danish populationbased analysis of 105 mantle cell lymphoma patients : incidences, clinical features, response, survival and prognostic factors, Eur. J. Cancer, vol.38, issue.3, pp.401-408, 2002.

P. Kalata, P. Martus, H. Zettl, C. Rödel, W. Hohenberger et al., Rainer Fietkau, and German Rectal Cancer Study Group. Differences between clinical trial participants and patients in a population-based registry : the German Rectal Cancer Study vs. the Rostock Cancer Registry

, Dis. Colon Rectum, vol.52, issue.3, pp.425-437, 2009.

J. Seppanen, S. Heinävaara, K. Holli, and T. Hakulinen, Comparison of cancer registry and clinical data as predictors for breast cancer survival, Cancer Causes Control, vol.19, issue.10, pp.1299-1304, 2008.

C. Terschuren, S. Gierer, C. Brillant, U. Paulus, M. Loffler et al., Are patients with Hodgkin lymphoma and high-grade non-Hodgkin lymphoma in clinical therapy optimization protocols representative of these groups of patients in Germany ?, Ann. Oncol, vol.21, issue.10, pp.2045-2051, 2010.

A. Cherubini, F. Pierri, B. Gasperini, E. Zengarini, A. Cerenzia et al., Are ongoing trials on hematologic malignancies still excluding older subjects ?, Haematologica, vol.98, issue.7, pp.997-1000, 2013.

J. Lemieux, C. Amireault, S. Camden, and J. Poulin, Evaluation of factors associated with recruitment in hematological clinical trials : a retrospective cohort study, Hematology, vol.15, issue.6, pp.373-377, 2010.

C. A. Townsley, R. Selby, and L. L. Siu, Systematic Review of Barriers to the Recruitment of Older Patients With Cancer Onto Clinical Trials, JCO, vol.23, issue.13, pp.3112-3124, 2005.

N. Becker, A. Silvia-de-sanjose, M. Nieters, L. Maynadié, P. L. Foretova et al.,

P. Boffetta, Birth order, allergies and lymphoma risk : Results of the European collaborative research project Epilymph, Leukemia Research, vol.31, issue.10, pp.1365-1372, 2007.

P. Cocco, G. Satta, S. Dubois, C. Pili, M. Pilleri et al.,

M. G. Miligi, P. Ennas, and . Boffetta, Lymphoma risk and occupational exposure to pesticides : results of the Epilymph study, Occup Environ Med, vol.70, issue.2, pp.91-98, 2013.

A. J. Andrea-t-mannetje, P. De-roos, R. Boffetta, G. Vermeulen, L. Benke et al., Tongzhang Zheng, Pierluigi Cocco, and Anne Kricker. Occupation and Risk of Non-Hodgkin Lymphoma and Its Subtypes : A Pooled Analysis from the InterLymph Consortium, 2015.

K. E. Smedby, J. N. Sampson, J. J. Turner, S. L. Slager, M. Maynadié et al., Medical history, lifestyle, family history, and occupational risk factors for mantle cell lymphoma : the InterLymph NonHodgkin Lymphoma Subtypes Project, J. Natl. Cancer Inst. Monographs, issue.48, pp.76-86, 2014.

N. Angeliki, . Florou, C. H. Ioannis, S. K. Gkiozos, K. N. Tsagouli et al., Clinical significance of smoking cessation in subjects with cancer : a 30-year review, Respir Care, vol.59, issue.12, pp.1924-1936, 2014.